D-0668-2022 Class I Terminated
FDA drug recall D-0668-2022 was initiated by Blaine Labs Inc on Jan 25, 2022 and is designated Class I. Reason for recall: Microbial Contamination of Non-sterile Product; FDA analysis found the product to be contaminated with Bacillus cereus. The recall status is terminated (terminated Aug 1, 2022). Affected quantity: 1119 (1 oz.) bottles/ 772 (3 oz.) tubes.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 30, 2022
- Initiation Date
- Jan 25, 2022
- Termination Date
- Aug 1, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1119 (1 oz.) bottles/ 772 (3 oz.) tubes
Product description
REVITADERM WOUND CARE GEL, (Benzalkonium Chloride in a gel containing transforming growth factor-b), 0.1%, packaged in 29.6 mL (1.0 FL OZ) bottles (NDC 63347-120-02) and 88.7 mL (3.0 FL OZ) tubes (NDC 63347-120-01), Blaine Labs Inc., Santa Fe Springs, CA 90670
Reason for recall
Microbial Contamination of Non-sterile Product; FDA analysis found the product to be contaminated with Bacillus cereus.
Distribution pattern
Nationwide in 17 States to 45 doctors.
Code information
Lot/Batch #: BL 2844, Expiration date 2/19/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0668-2022
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026